Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

This study tests combining two targeted drugs — vebreltinib (a MET inhibitor) and PLB1004 (a third-generation EGFR inhibitor) — for patients with advanced lung cancer that initially responded to EGFR-targeted therapy but has since developed resistance through a MET pathway change. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic non-small cell lung cancer - Your tumor has an EGFR mutation (exon 19 deletion or L858R) - Your tumor has developed MET amplification or MET overexpression after EGFR-targeted therapy - You have at least one measurable tumor lesion - You are in generally good health (ECOG 0–1) **You may NOT be eligible if...** - You have previously received a MET inhibitor or anti-HGF therapy - Your tumor also has ALK or ROS1 alterations - You have symptomatic brain metastases requiring increasing steroid doses - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.